Press Releases



    • JAN 16 2018

    Oncoceutics and Frontida BioPharm Announce Product Development and Commercialization Partnership

    Philadelphia, PA (January 16, 2018) –Oncoceutics Inc. and Frontida BioPharm, Inc. announced that the two companies have entered into a product development and commercialization agreement to further develop and scale-up the finished product manufacturing process for ONC201, Oncoceutics’ lead molecule. ONC201 is an antagonist of the G-protein coupled receptor (GPCR) dopamine receptor D2 (DRD2) and

    • JAN 08 2018

    Oncoceutics Extends IP Coverage to Japan with New Patent Covering All Cancers

     Oncoceutics Extends IP Coverage to Japan with New Patent Covering All Cancers Philadelphia, PA (January 8, 2018) – Oncoceutics, Inc. announced that the Japanese Patent Office (JPO) has issued Japanese Patent No. 6132833 for the use of ONC201 to treat all cancers or patients having a risk of cancer, including brain, colon, breast, colorectal cancers,

    • DEC 19 2017

    Oncoceutics Extends Composition of Matter Patent Portfolio to ONC212

    Philadelphia, PA (December 19, 2017) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) issued patent #9,845,324, providing the company with composition of matter protection for ONC212 and several additional small molecules derived from Oncoceutics’ lead compound ONC201. ONC212 is one of the lead follow-on compounds in the company’s development pipeline

    • NOV 13 2017

    Effectiveness of ONC201 in H3 K27M Glioma to be Presented at SNO

    Philadelphia, PA (November 13, 2017) – Oncoceutics, Inc. today announced that five clinical and preclinical presentations on ONC201 and ONC206 for the treatment of high grade gliomas will be presented at the 22nd Annual Scientific Meeting and Education Day of the Society of Neuro-Oncology, held November 16th-19th in San Francisco. The series of presentations describe